These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30067619)

  • 1. Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
    Gandhi L
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):484-485. PubMed ID: 30067619
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Targeted therapies in non-small cell lung cancer in 2014].
    Leduc C; Besse B
    Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
    Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problems involved in the clinical trials for non-small cell lung carcinoma.
    Saijo N
    Cancer Treat Rev; 2012 May; 38(3):194-202. PubMed ID: 21775064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis.
    Wang Z; Yang H; Luo S; Liu B; Zhang N; Li L; Zhou S; Shen R; Xie X
    Lung Cancer; 2017 Oct; 112():1-9. PubMed ID: 29191580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
    Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
    Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.
    Stinchcombe TE; Borghaei H; Barker SS; Treat JA; Obasaju C
    Clin Lung Cancer; 2016 Jan; 17(1):1-9. PubMed ID: 26340853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
    BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.
    Bennouna J
    Future Oncol; 2017 Sep; 13(21):1829-1833. PubMed ID: 28657354
    [No Abstract]   [Full Text] [Related]  

  • 14. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years.
    Cufer T; Ovcaricek T; O'Brien ME
    Eur J Cancer; 2013 Apr; 49(6):1216-25. PubMed ID: 23265700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
    Pirker R
    Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
    Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
    BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
    J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.